Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.

Hochstetler H, Trzepacz PT, Wang S, Yu P, Case M, Henley DB, Degenhardt E, Leoutsakos JM, Lyketsos CG.

J Alzheimers Dis. 2016;50(1):271-82. doi: 10.3233/JAD-150563.

2.

APOEε2 is associated with milder clinical and pathological Alzheimer disease.

Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT.

Ann Neurol. 2015 Jun;77(6):917-29. doi: 10.1002/ana.24369.

3.

Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Leoutsakos JM, Forrester SN, Corcoran CD, Norton MC, Rabins PV, Steinberg MI, Tschanz JT, Lyketsos CG.

Int J Geriatr Psychiatry. 2015 Aug;30(8):824-32. doi: 10.1002/gps.4221. Epub 2014 Nov 3.

4.

Neural correlates of cognitive intervention in persons at risk of developing Alzheimer's disease.

Hosseini SM, Kramer JH, Kesler SR.

Front Aging Neurosci. 2014 Aug 26;6:231. doi: 10.3389/fnagi.2014.00231. eCollection 2014. Review.

5.

Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment.

Bosco P, Ferri R, Salluzzo MG, Castellano S, Signorelli M, Nicoletti F, Nuovo SD, Drago F, Caraci F.

Curr Genomics. 2013 Apr;14(2):147-56. doi: 10.2174/1389202911314020007.

6.

Alternative Approaches in Gene Discovery and Characterization in Alzheimer's Disease.

Ertekin-Taner N, De Jager PL, Yu L, Bennett DA.

Curr Genet Med Rep. 2013 Mar;1(1):39-51. Epub 2013 Jan 22.

7.

A random change point model for cognitive decline in Alzheimer's disease and mild cognitive impairment.

Yu L, Boyle P, Wilson RS, Segawa E, Leurgans S, De Jager PL, Bennett DA.

Neuroepidemiology. 2012;39(2):73-83. doi: 10.1159/000339365. Epub 2012 Jul 17.

8.

Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease.

Mielke MM, Leoutsakos JM, Tschanz JT, Green RC, Tripodis Y, Corcoran CD, Norton MC, Lyketsos CG.

J Alzheimers Dis. 2011;26(1):127-34. doi: 10.3233/JAD-2011-110086.

9.

Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future.

Freitas C, Mondragón-Llorca H, Pascual-Leone A.

Exp Gerontol. 2011 Aug;46(8):611-27. doi: 10.1016/j.exger.2011.04.001. Epub 2011 Apr 14. Review.

10.

Increased functional brain response during word retrieval in cognitively intact older adults at genetic risk for Alzheimer's disease.

Wierenga CE, Stricker NH, McCauley A, Simmons A, Jak AJ, Chang YL, Delano-Wood L, Bangen KJ, Salmon DP, Bondi MW.

Neuroimage. 2010 Jul 1;51(3):1222-33. doi: 10.1016/j.neuroimage.2010.03.021. Epub 2010 Mar 16.

11.

Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia.

Reitz C, Mayeux R.

J Alzheimers Dis. 2010;19(1):229-51. doi: 10.3233/JAD-2010-1255. Review.

12.

Use of genetic variation as biomarkers for Alzheimer's disease.

Reitz C, Mayeux R.

Ann N Y Acad Sci. 2009 Oct;1180:75-96. doi: 10.1111/j.1749-6632.2009.04945.x. Review.

13.

Endophenotypes in normal brain morphology and Alzheimer's disease: a review.

Reitz C, Mayeux R.

Neuroscience. 2009 Nov 24;164(1):174-90. doi: 10.1016/j.neuroscience.2009.04.006. Epub 2009 Apr 9. Review.

14.

Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR.

Arch Gen Psychiatry. 2009 Jan;66(1):81-7. doi: 10.1001/archgenpsychiatry.2008.516.

15.

Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.

Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, Irizarry MC.

Arch Neurol. 2008 Jun;65(6):776-85. doi: 10.1001/archneur.65.6.776.

16.

APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.

Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, Blacker D, Stern Y.

Neurology. 2008 May 6;70(19 Pt 2):1842-9. doi: 10.1212/01.wnl.0000304038.37421.cc. Epub 2008 Apr 9.

17.

Neuropsychological deficits associated with Alzheimer's disease in the very-old: discrepancies in raw vs. standardized scores.

Bondi MW, Houston WS, Salmon DP, Corey-Bloom J, Katzman R, Thal LJ, Delis DC.

J Int Neuropsychol Soc. 2003 Jul;9(5):783-95.

18.

Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype.

Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ.

J Int Neuropsychol Soc. 2002 Nov;8(7):943-55.

19.

Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence.

Jelic V, Julin P, Shigeta M, Nordberg A, Lannfelt L, Winblad B, Wahlund LO.

J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):59-65.

Supplemental Content

Support Center